Summary & Overview
HCPCS J0713: Injection, Ceftazidime, per 500 mg
HCPCS Level II code J0713 designates the injectable antibiotic ceftazidime, billed per 500 mg unit. As a commonly used broad-spectrum cephalosporin for serious gram-negative infections, this code is critical for hospital-based and acute care medication billing and inventory management. Accurate use of J0713 affects claims processing, drug cost reporting, and clinical documentation across inpatient and outpatient settings nationally.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J0713 is defined, typical sites of service where the drug is administered, and common billing considerations tied to unit-based billing for parenteral antibiotics. The publication also summarizes benchmarks and common modifiers used with HCPCS drug codes, policy updates that influence drug billing and reimbursement, and the clinical context in which ceftazidime is indicated.
The content is intended to help coding professionals, revenue cycle staff, and policy analysts understand the role of J0713 in claims, what documentation supports its use, and where to look for payer-specific policies. Data not available in the input will be noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J0713 represents the drug injection ceftazidime, billed per 500 mg. This code denotes administration of an intravenous or intramuscular antibacterial agent used to treat serious gram-negative bacterial infections.
Service type: Injection (medication administration)
Typical site of service: Hospital outpatient department, inpatient facility, emergency department, or other settings where parenteral antibiotics are administered
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0713 is an adult or pediatric patient with a serious Gram-negative bacterial infection—commonly complicated urinary tract infection, intra-abdominal infection, hospital-acquired pneumonia, or bacteremia—requiring parenteral ceftazidime. The care pathway begins with clinical assessment in the emergency department, inpatient ward, or outpatient infusion center, where a treating clinician documents indication, weight-based dose calculation (dosing intervals per renal function), and route of administration. Pharmacy verifies the ceftazidime concentration and prepares the intravenous dose in 500 mg increments. Nursing administers the injection or infusion via peripheral IV or central line, monitors for infusion reactions, documents lot number and amount administered, and records the appropriate HCPCS level II code J0713 per 500 mg vial on the medication administration record and claim. Ancillary services commonly include microbiology cultures, renal function testing, and therapeutic monitoring; doses are adjusted for renal impairment and in consultation with infectious disease when needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to patient |